End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012.

ABSTRACT:

Introduction

Although the management of scleroderma continues to evolve, it is unknown whether the burden of end-stage kidney disease (ESKD) treated with maintenance renal replacement therapy from SD has changed.

Methods

We examined United States Renal Data System data (n = 1,677,303) for the years 1996 to 2012 to quantify the incidence and outcomes of ESKD from scleroderma treated with renal replacement therapy (n = 2398). Outcomes assessed through demography-matched scleroderma-positive/scleroderma-negative comparisons included recovery of kidney function, mortality, listing for transplant, renal transplantations, and graft failure.

Results

Overall ESKD rates from scleroderma were 0.5 per million per year. Adjusted incidence ratios fell over time, to 0.42 in 2012 (v

SUBMITTER: Sexton DJ 

PROVIDER: S-EPMC5762953 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature